Apoe3 (Apolipoprotein E3) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Pathway / Mechanism Diagram
graph TD
A["APOE Gene"] --> B["APOE e2 (Protective)"]
A --> C["APOE e3 (Neutral)"]
A --> D["APOE e4 (Risk Factor)"]
D --> E["Impaired Abeta Clearance"]
D --> F["Enhanced Tau Phosphorylation"]
D --> G["BBB Dysfunction"]
D --> H["Reduced Lipid Transport"]
E --> I["Amyloid Accumulation"]
F --> J["Tangle Formation"]
G --> K["Neuroinflammation"]
H --> L["Impaired Synaptic Repair"]
I --> M["Neurodegeneration"]
J --> M
K --> M
L --> M
B --> N["Enhanced Abeta Clearance"]
N --> O["Reduced AD Risk"]
style D fill:#ef5350,color:#e0e0e0
style B fill:#1b5e20,color:#e0e0e0
style M fill:#ef5350,color:#e0e0e0
Introduction
Apoe3 (Apolipoprotein E3) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@taf]
...
APOE3 (Apolipoprotein E3)
Overview
Apoe3 (Apolipoprotein E3) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Pathway / Mechanism Diagram
Mermaid diagram (expand to render)
Introduction
Apoe3 (Apolipoprotein E3) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@taf]
Apolipoprotein E3 (APOE3) is the most common allele of the [APOE](/proteins/apoe) gene, representing the "gold standard" or reference allele for comparing the effects of APOE2 (protective) and APOE4 (risk-increasing). It serves as the benchmark for understanding how different APOE alleles influence Alzheimer's disease (AD) risk, lipid metabolism, and neural repair mechanisms [1, 2]. [@crisprbased]
Genetic Background
Gene: APOE (Apolipoprotein E)
Chromosome: 19q13.32
SNP ID: rs429358 (Arg130), rs7412 (Arg176)
Allele Frequency: ~70-80% in Caucasian populations; ~50-60% globally
Inheritance: Co-dominant (one copy from each parent)
Nucleotide Changes: C→T at rs429358 (Arg130), C→T at rs7412 (Arg176)
Structure and Function
APOE3 contains: [@prmtmediated]
Arg130 (cysteine in APOE2)
Arg176 (cysteine in APOE2)
APOE3 represents the "wild-type" with balanced function: [@nanobodybased]
Intermediate lipid binding capacity — binds to LDL receptors with ~40-50% efficiency of APOE4
Normal receptor binding to LDLR and [LRP1](/proteins/lrp1)
Standard [amyloid-beta](/proteins/amyloid-beta) interaction properties — intermediate Aβ42 aggregation propensity
N-terminal domain: Receptor-binding region (residues 1-191)
C-terminal domain: Lipid-binding region (residues 216-299)
Alzheimer's Disease Association
Neutral Effects
Baseline Risk: APOE3 carriers have the population average AD risk (approximately 10-15% lifetime risk)
Age of Onset: Average age of onset for sporadic AD (~75-85 years)
Amyloid Deposition: Intermediate burden on PET imaging — less than APOE4, more than APOE2
Cognitive Trajectory: Age-related cognitive decline comparable to non-carriers
Mechanistic Role
APOE3 serves as the functional baseline for comparing other alleles [3]: [^6]
[Aβ](/proteins/amyloid-beta) Clearance: Normal astrocyte and [microglia](/entities/microglia)-mediated clearance via LDLR and LRP1
Lipid Metabolism: Standard lipoprotein particle metabolism in CSF and plasma
Neuroprotection: Intermediate neuroinflammatory response compared to APOE4 (pro-inflammatory) and APOE2 (anti-inflammatory)
Synaptic Function: Normal maintenance and plasticity — dendritic spine density maintained with age
[Tau](/proteins/tau) Pathology: Intermediate susceptibility to tau-mediated neurodegeneration
Cerebral Glucose Metabolism: Normal FDG-PET patterns compared to APOE4 carriers showing hypometabolism
Apoe3 (Apolipoprotein E3) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Background
The study of Apoe3 (Apolipoprotein E3) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
Recent Research (2024-2026)
This section highlights recent publications relevant to this disease.
[APOE4 drives widespread changes to the hepatic proteome and alters metabolic function.](https://pubmed.ncbi.nlm.nih.gov/41797922/) (2026 Mar 20) - iScience
[TAF15 promotes the healing of diabetic foot ulcers by mediating the transcriptional activation of APOE through CEBPB to regulate PTX3.](https://pubmed.ncbi.nlm.nih.gov/41805994/) (2026 Mar 10) - Molecular genetics and genomics : MGG
[CRISPR-based correction of apolipoprotein E4 in Alzheimer's disease: Therapeutic strategies and macromolecular delivery innovations.](https://pubmed.ncbi.nlm.nih.gov/41812941/) (2026 Mar 9) - International journal of biological macromolecules
[PRMT3-Mediated Arginine Methylation Stabilizes PCSK9 to Promote Aortic Valve Calcification.](https://pubmed.ncbi.nlm.nih.gov/41797709/) (2026 Mar 9) - Circulation
[A Nanobody-Based Toolbox to Probe ApoE4 in the Secretory Pathway and Cytosol.](https://pubmed.ncbi.nlm.nih.gov/41827912/) (2026 Mar 6) - Cells